An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
<p>Abstract</p> <p>Background</p> <p>MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working mechanisms. The purpose of this study was to evaluate an...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-12-01
|
| Series: | Molecular Cancer |
| Online Access: | http://www.molecular-cancer.com/content/8/1/115 |
| _version_ | 1828297981057564672 |
|---|---|
| author | Yang Dajun Wu Sherwin Sosin Angela Aboukameel Amro Azmi Asfar S Wu Jack Mohammad Ramzi M Wang Shaomeng Al-Katib Ayad M |
| author_facet | Yang Dajun Wu Sherwin Sosin Angela Aboukameel Amro Azmi Asfar S Wu Jack Mohammad Ramzi M Wang Shaomeng Al-Katib Ayad M |
| author_sort | Yang Dajun |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working mechanisms. The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line. For comparison purpose, MI-319, MI-219 and Nutlin-3 were assessed side by side against FSCCL and three other B-cell hematological tumor cell lines in growth inhibition and gene expression profiling experiments.</p> <p>Results</p> <p>MI-319 was shown to bind to MDM2 protein with an affinity slightly higher than that of MI-219 and Nutlin-3. Nevertheless, cell growth inhibition and gene expression profiling experiments revealed that the three compounds have quite similar potency against the tumor cell lines tested in this study. <it>In vitro</it>, MI-319 exhibited the strongest anti-proliferation activity against FSCCL and four patient cells, which all have wild-type p53. Data obtained from Western blotting, cell cycle and apoptosis analysis experiments indicated that FSCCL exhibited strong cell cycle arrest and significant apoptotic cell death; cells with mutant p53 did not show significant apoptotic cell death with drug concentrations up to 10 μM, but displayed weaker and differential cell cycle responses. In our systemic mouse model for FSCCL, MI-319 was tolerated well by the animals, displayed effectiveness against FSCCL-lymphoma cells in blood, brain and bone marrow, and achieved significant therapeutic impact (p < 0.0001) by conferring the treatment group a > 28% (%ILS, 14.4 days) increase in median survival days.</p> <p>Conclusion</p> <p>Overall, MI-319 probably has an anti-lymphoma potency equal to that of MI-219 and Nutlin-3. It is a potent agent against FSCCL <it>in vitro </it>and <it>in vivo </it>and holds the promises to be developed further for the treatment of follicular lymphoma that retains wild-type p53.</p> |
| first_indexed | 2024-04-13T12:33:41Z |
| format | Article |
| id | doaj.art-81a58f5fbce244b69ec40a23e23173f1 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-13T12:33:41Z |
| publishDate | 2009-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-81a58f5fbce244b69ec40a23e23173f12022-12-22T02:46:43ZengBMCMolecular Cancer1476-45982009-12-018111510.1186/1476-4598-8-115An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animalsYang DajunWu SherwinSosin AngelaAboukameel AmroAzmi Asfar SWu JackMohammad Ramzi MWang ShaomengAl-Katib Ayad M<p>Abstract</p> <p>Background</p> <p>MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working mechanisms. The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line. For comparison purpose, MI-319, MI-219 and Nutlin-3 were assessed side by side against FSCCL and three other B-cell hematological tumor cell lines in growth inhibition and gene expression profiling experiments.</p> <p>Results</p> <p>MI-319 was shown to bind to MDM2 protein with an affinity slightly higher than that of MI-219 and Nutlin-3. Nevertheless, cell growth inhibition and gene expression profiling experiments revealed that the three compounds have quite similar potency against the tumor cell lines tested in this study. <it>In vitro</it>, MI-319 exhibited the strongest anti-proliferation activity against FSCCL and four patient cells, which all have wild-type p53. Data obtained from Western blotting, cell cycle and apoptosis analysis experiments indicated that FSCCL exhibited strong cell cycle arrest and significant apoptotic cell death; cells with mutant p53 did not show significant apoptotic cell death with drug concentrations up to 10 μM, but displayed weaker and differential cell cycle responses. In our systemic mouse model for FSCCL, MI-319 was tolerated well by the animals, displayed effectiveness against FSCCL-lymphoma cells in blood, brain and bone marrow, and achieved significant therapeutic impact (p < 0.0001) by conferring the treatment group a > 28% (%ILS, 14.4 days) increase in median survival days.</p> <p>Conclusion</p> <p>Overall, MI-319 probably has an anti-lymphoma potency equal to that of MI-219 and Nutlin-3. It is a potent agent against FSCCL <it>in vitro </it>and <it>in vivo </it>and holds the promises to be developed further for the treatment of follicular lymphoma that retains wild-type p53.</p>http://www.molecular-cancer.com/content/8/1/115 |
| spellingShingle | Yang Dajun Wu Sherwin Sosin Angela Aboukameel Amro Azmi Asfar S Wu Jack Mohammad Ramzi M Wang Shaomeng Al-Katib Ayad M An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals Molecular Cancer |
| title | An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals |
| title_full | An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals |
| title_fullStr | An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals |
| title_full_unstemmed | An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals |
| title_short | An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals |
| title_sort | mdm2 antagonist mi 319 restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals |
| url | http://www.molecular-cancer.com/content/8/1/115 |
| work_keys_str_mv | AT yangdajun anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT wusherwin anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT sosinangela anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT aboukameelamro anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT azmiasfars anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT wujack anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT mohammadramzim anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT wangshaomeng anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT alkatibayadm anmdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT yangdajun mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT wusherwin mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT sosinangela mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT aboukameelamro mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT azmiasfars mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT wujack mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT mohammadramzim mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT wangshaomeng mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals AT alkatibayadm mdm2antagonistmi319restoresp53functionsandincreasesthelifespanoforallytreatedfollicularlymphomabearinganimals |